SSG
UTHR icon

Summit Securities Group’s United Therapeutics UTHR Stock Holding History

Summit Securities Group’s Portfolio UTHR Stock Details UTHR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-188
Closed -$78.8K – 1266
2025
Q3 		$78.8K Buy
+188
New +$63.2K 0.02% 448
2015
Q1 		– Sell
-100
Closed -$13K – 645
2014
Q4 		$13K Buy
+100
New +$12.9K ﹤0.01% 435
2014
Q2 		– Sell
-200
Closed -$19K – 656
2014
Q1 		$19K Buy
+200
New +$20.5K 0.01% 237
2013
Q3 		– Sell
-150
Closed -$10K – 557
2013
Q2 		$10K Buy
+150
New +$9.66K ﹤0.01% 325

Other funds holding UTHR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
AssetMark Inc
AssetMark Inc Concord, California $58.2B AUM 22.78% 1-Year Est. Return

Summit Securities Group's UTHR Position: Q4 2025 in Review

Summit Securities Group sold out of United Therapeutics (UTHR) in Q4 2025, closing a stake of 188 shares — an estimated $78.8K sold.

Summit Securities Group first reported a position in UTHR in Q2 2013 and held it in 4 quarters. The position peaked at $78.8K in Q3 2025. 838 funds tracked by Wall St. Rank hold UTHR as of Q4 2025.

  • Summit Securities Group reported no remaining United Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Summit Securities Group sold 188 United Therapeutics shares in Q4 2025, an estimated $78.8K.
  • Summit Securities Group first reported a position in United Therapeutics in Q2 2013 and held it in 4 quarters.
  • Summit Securities Group's United Therapeutics position peaked at $78.8K in Q3 2025.
  • 838 funds tracked by Wall St. Rank held United Therapeutics as of Q4 2025.

Based on Summit Securities Group's 13F filing for Q4 2025, filed 17 Feb 2026.